Skip to main content
. Author manuscript; available in PMC: 2012 Mar 16.
Published in final edited form as: Bioconjug Chem. 2011 Feb 7;22(3):413–421. doi: 10.1021/bc100432h

FIGURE 3.

FIGURE 3

Analysis of Affibody-HSA bioconjugates. (A) MALDI-TOF-MS of DOTA-HSA-ZHER2:342. The number of Affibody molecules per HSA is calculated to be 1 to 5. (a), DOTA-HSA-SMCC 68.56 kDa; (b), DOTA-HSA-ZHER2:342(1) (MW=75.03); (c), DOTA-HSA-ZHER2:342(2) (MW=82.09); (d), DOTA-HSA-ZHER2:342(3) (MW= 89.19); (e), DOTA-HSA-ZHER2:342(4) (95.8 kDa) and (f), DOTA-HSA-ZHER2:342(5) (MW= 102.19) (B) SDS-PAGE analysis of several fractions obtained from the chemical conjugation procedure of HSA with ZHER2:342. 1, HSA; 2, Ac-Cys-ZHER2:342; 3, reaction mixture of DOTA-HSA and ZHER2:342 (DOTA-HSA-ZHER2:342); 4, flow-through fraction after centrifugation using microcentrifuge tubes; 5, purified DOTA-HSA-ZHER2:342. 241×120mm (150 × 150 DPI)